Allogeneic CAR T Cema-Cel Boosts MRD Clearance in LBCL

Cemacabtagene ansegedleucel (cema-cel) demonstrated a higher rate of minimal residual disease (MRD) clearance compared with observation in patients with large B-cell lymphoma (LBCL) receiving first-line consolidation therapy, according to an interim futility analysis of the phase 2 ALPHA3 trial (NCT06500273).¹

Among the first 24 patients randomized and assessed for MRD at day 45, 58.3% of patients who received the allogeneic CD19-directed chimeric antigen receptor T-cell (CAR T) therapy achieved MRD clearance vs 16.7% among those who were assigned to standard-of-care observation, amounting to a 41.6% absolute difference in MRD clearance between arms. Given the observed difference favoring cema-cel, which met a prespecified futility boundary, the study will continue to evaluate its primary and key secondary end points.

In addition, cema-cel was well-tolerated, with no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-vs-host disease (GVHD) reported as treatment-emergent adverse events of special interest. Two cases of low-grade infections were reported in each study arm; other low-grade neurologic events were reported in 6 patients in the cema-cel arm and 1 patient in the observation arm. There were no hospitalizations for treatment-related adverse events, with 10 of 12 patients receiving cema-cel managed entirely in the outpatient setting.

Feasibility in the Community Setting

Notably, community cancer centers constituted approximately one-third of screening and cema-cel infusion sites in the study, underscoring the feasibility of delivering the CAR T therapy in settings outside academic centers. This distribution reflects an intentional effort to evaluate the therapy in practice environments where the majority of patients with LBCL receive care.

Cema-cel is an allogeneic, gene-edited CAR T-cell product targeting CD19. Unlike autologous CAR T-cell therapies, which require patient-specific manufacturing, this approach uses donor-derived T cells engineered to reduce GVHD risk and allow for off-the-shelf availability. The potential for rapid administration may be particularly relevant in consolidation settings where timing after frontline therapy is critical, as well as conducive for use in community care settings, where delays associated with manufacturing and referral to specialized centers may limit access to cellular therapies.

“In busy community practices, the goal is simple: bring the therapy to the patient, not the patient to the therapy,” said Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, in a news release.¹ “Historically, CAR T has largely been out of reach for community practices. The ability to deliver an off-the-shelf CAR T safely in the community setting, potentially outpatient, could address far more patients and extend treatment reach across the communities we serve.”

About the ALPHA3 Trial

The ALPHA3 trial is a randomized, open-label phase 2 trial evaluating the efficacy and safety of cema-cel in adult patients with LBCL who have MRD after complete or partial response to first-line therapy against standard of care observation.² The trial’s primary end point is event-free survival; key secondary end points include progression-free survival, overall survival, safety, and MRD clearance.

For treatment, patients have been randomized 1:1 to either receive consolidation with cema-cel following lymphodepletion with fludarabine and cyclophosphamide or undergo observation (n = 12 each).

MRD status is determined using the Foresight CLARITY™ Investigational Use Only (IUO) MRD assay, and those who exhibit MRD positivity after a response to a full course of standard first-line therapy (per PET/CT) are included in the study. Patients must not have had prior treatment with anti-CD19 targeted therapies, a history of central nervous system involvement, active and clinically significant autoimmune disease, or active systemic infections.

Enrollment into the study is ongoing through year-end 2027 for an estimated total population of 250 patients, with additional analyses planned to assess efficacy outcomes. If positive, the study could support a novel consolidation strategy for patients at high risk of relapse after initial therapy.

REFERENCES

1. Allogene Therapeutics reports interim futility analysis from pivotal ALPHA3 trial showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation LBCL. News release. Allogene Therapeutics. April 13, 2026. Accessed April 15, 2026. https://tinyurl.com/3e7bvn56

2. Consolidation of first-line MRD+ remission with cema-cel in patients with LBCL (ALPHA3). ClinicalTrials.gov. Updated March 18, 2026. Accessed April 15, 2026. https://clinicaltrials.gov/study/NCT06500273